• BTD: Making Sense of M&A, Alliances and Divestments

  • By: Carlos Keener
  • Podcast

BTD: Making Sense of M&A, Alliances and Divestments

By: Carlos Keener
Listen for free

  • Summary

  • BTD is a specialist consultancy that helps people around the world achieve their long-term acquisition, divestment and alliance goals. BTD looks Beyond the Deal, working in partnership with our clients so that they find and complete deals and alliances that build strategic capabilities; ensure that the deals being considered will be successful post-close; deliver the benefits and objectives of their deals quickly, efficiently and cost-effectively, maintain focus on business as usual during and after the deal process and strengthen their own ability to do deals and alliances consistently well in future. Established in 2001, BTD has worked with over 100 clients around the world including Amadeus, Coca-Cola, E.On, GlaxoSmithKline, and Unilever. With offices in London and Boston and an international team, BTD helps leaders reduce deal time and cost, increase deal value, raise capability and maintain a high-performing businesses through the process. Our bespoke services and collaborative approach delivers confidence in the final outcome while ensuring they stay in full control of the process. From pre-deal to post-close – Go Beyond.
    © 2024 BTD: Making Sense of M&A, Alliances and Divestments
    Show More Show Less
Economics
Show More Show Less
Episodes
  • BTD Consulting Alliance Matters Podcast: Cancer Research Horizons - De-Risking Oncology Development

    BTD Consulting Alliance Matters Podcast: Cancer Research Horizons - De-Risking Oncology Development
    Jan 31 2023

    One in two people will develop some form of cancer in their lifetimes. Despite decades of work, one-sixth of worldwide deaths are due to cancer. High-stakes research underpinned by strong alliances are making possible new therapies, bringing new hope.


    In this podcast, Julie Little (Associate Director of Strategic Alliances) and Steve Wedge (Chief Scientific Officer) of Cancer Research UK discuss their organisation’s major role de-risking oncology research. CRUK has catalysed collaborations including biotech startups and big pharmaceutical companies alike. The newly formed Cancer Research Horizons will supercharge that mission.

    BTD’s Nick Palmer leads the discussion. Learn more. Give it a listen.

    #podcast #startups #biotech #research #oncology #pharmaceutical #alliances
    Show More Show Less
    35 mins
  • Meet the BTD Team: Louise Cooper, Managing Consultant

    Meet the BTD Team: Louise Cooper, Managing Consultant
    Oct 25 2021

    A senior project, programme and integration professional, Louise Cooper joined the BTD team several years ago and has supported some of our largest and most complex engagements with clients such as Spectris and Glatfelter. In this podcast, Louise explores the differences between integration and more general transformation programmes, and what she finds challenging and fulfilling in her integration, separation and restructuring work.

    www.btd.consulting
    CLICK HERE to follow us on LinkedIn
    Show More Show Less
    30 mins
  • Targeting Those Most in Need: Access-Focused Product Partnerships at Novartis

    Targeting Those Most in Need: Access-Focused Product Partnerships at Novartis
    Sep 16 2021

    All pharmaceutical companies look to leverage their capabilities to benefit those in the World’s poorest countries. Novartis aims to go beyond corporate philanthropy to create a more sustainable therapy-development model. By marshalling partnerships and its own people, Charlie Bailey leads Novartis teams pursuing development initiatives addressing better-known conditions like malaria, as well as more obscure ones like leishmaniasis. These initiatives can span a decade or more taking therapies through Phase I, II and III clinical trials, then ensuring the infrastructure and skills to offer them in the world’s most remote locations.

    In this fascinating podcast, Charlie discusses the ideas behind Novartis’s access-focused product partnerships with BTD partner, Nick Palmer. Charlie explains how this new model offers a more sustainable path to addressing suffering in the Third World. Working with NGOs ranging from the Wellcome Trust and the Gates Foundation, to specialised ones like DNDi and MMV, Novartis is charting a course to bring First World therapies to the Third world, AND to push the boundaries of pharmaceutical innovation. He discusses specific examples and experiences to highlight this exciting approach.


    CLICK HERE to follow us on LinkedIn
    www.btd.consulting
    Show More Show Less
    53 mins

What listeners say about BTD: Making Sense of M&A, Alliances and Divestments

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.